Form 4: INSMED CMO Exercises Options, Sells Shares

INSMED's Chief Medical Officer, Martina M.D. Flammer, exercised stock options and subsequently sold an equivalent number of shares under a pre-arranged 10b5-1 trading plan.

Summary

• Martina M.D. Flammer, Chief Medical Officer of INSMED Inc. (INSM), engaged in a series of transactions on November 11, 2025.
• Flammer exercised stock options to acquire a total of 31,226 shares of common stock.
• Specifically, 12,949 shares were acquired at an exercise price of $17.07 per share, and 18,277 shares were acquired at an exercise price of $18.95 per share.
• Concurrently, Flammer sold a total of 31,226 shares of common stock in multiple transactions.
• Sales included 5,467 shares at a weighted average price of $188.38, 12,224 shares at $189.36, 10,622 shares at $190.33, and 2,913 shares at $191.04.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2025.
• Following these transactions, Flammer directly beneficially owns 83,111 shares of common stock.
• Additionally, Flammer directly beneficially owns 12,949 stock options with a $17.07 exercise price and 54,833 stock options with a $18.95 exercise price.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing reports routine, pre-planned insider transactions (exercise of options and subsequent sale of shares) under a 10b5-1 plan. This does not reflect new discretionary action or a change in management's outlook on the company's prospects.

Positives

• The exercise of stock options by a Chief Medical Officer indicates a realization of value from long-term incentive compensation.
• The high sale prices for the common stock, ranging from $188.38 to $191.04, demonstrate significant appreciation from the exercise prices of $17.07 and $18.95.

Negatives

• The sale of shares by an insider, even under a pre-arranged plan, can sometimes be perceived as a lack of conviction, though in this case, it's a routine liquidity event.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing represents a routine insider transaction for an executive at a publicly traded biotechnology company. Such transactions are common for executives managing their equity compensation and personal finances, often facilitated by 10b5-1 plans to avoid accusations of trading on material non-public information.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan aligns with best practices in corporate governance, allowing insiders to manage their equity holdings in a pre-scheduled and transparent manner, reducing the risk of insider trading allegations. This is a standard practice across industries for executives with significant equity compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: The transactions are routine and pre-planned, so they are unlikely to have a significant direct impact on shareholder sentiment or the company's operational outlook.
• Employees: No direct impact from this filing.
• Customers: No direct impact from this filing.
• Suppliers: No direct impact from this filing.
• Creditors: No direct impact from this filing.

Next Steps

• The remaining stock options will continue to vest according to their schedule: 25% on the first anniversary of the grant date and an additional 12.5% on each sixth-month anniversary thereafter through the fourth anniversary of the grant date.

Key Dates

Keywords

INSMED Inc., INSM, Form 4, Insider Transaction, Stock Options, Share Sale, Executive Compensation, 10b5-1 Plan, Chief Medical Officer